vTv Therapeutics appoints Deepa Prasad as President and CEO; Holcombe retires

vTv Therapeutics Inc.

Stephen Holcombe retired as CEO effective Oct 19, 2021; will serve as Strategic Advisor for one year, receiving $450k/yr severance through Dec 2022.
Deepa Prasad appointed President & CEO; base salary $650k, 100% bonus, options for 2,498,635 shares at $1.47.
Prasad brings 20+ years healthcare experience; was Managing Director at WestRiver Group, led investments in DSGN, Ginger, Curai.
Company to launch Phase 3 pivotal studies for TTP399, a Type 1 diabetes treatment with FDA Breakthrough Therapy Designation.
TTP399 Phase 2 showed significant HbA1c improvement and 40% reduction in symptomatic hypoglycemia vs placebo.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Deepa Prasad

President and Chief Executive Officer

VTVT · vTv Therapeutics Inc.

Effective: 2021-10-19
Filed: October 20, 2021, 7:59 PM ET

On the Effective Date, the Company announced that the Board has appointed Deepa Prasad as President and Chief Executive Officer and as a member of the Board.

Departed

Stephen Holcombe

Chief Executive Officer

VTVT · vTv Therapeutics Inc.

Effective: 2021-10-19
Successor: Deepa Prasad
Filed: October 20, 2021, 7:59 PM ET

On October 19, 2021, (the “Effective Date”) Stephen Holcombe announced his retirement as Chief Executive Officer and as an employee of vTv Therapeutics Inc. (the “Company”), effective as of the Effective Date.

Appointed

Deepa Prasad

Director

VTVT · vTv Therapeutics Inc.

Effective: 2021-10-19
Filed: October 20, 2021, 7:59 PM ET

On the Effective Date, the Company announced that the Board has appointed Deepa Prasad as President and Chief Executive Officer and as a member of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Deepa Prasad was appointed as President and Chief Executive Officer at vTv Therapeutics Inc..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

On the Effective Date, the Company announced that the Board has appointed Deepa Prasad as President and Chief Executive Officer and as a member of the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Stephen Holcombe retired as Chief Executive Officer at vTv Therapeutics Inc..

Action: retired
Role: Chief Executive Officer

Exact text from the filing

On October 19, 2021, (the “Effective Date”) Stephen Holcombe announced his retirement as Chief Executive Officer and as an employee of vTv Therapeutics Inc. (the “Company”), effective as of the Effective Date.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Deepa Prasad was appointed as Director at vTv Therapeutics Inc..

Action: appointed
Role: Director

Exact text from the filing

On the Effective Date, the Company announced that the Board has appointed Deepa Prasad as President and Chief Executive Officer and as a member of the Board.

View on SEC.gov

vTv Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0000950142-21-003244

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.